Evan Loh, M.D. has been Paratek’s Chief Executive Officer since June 2019. Prior to that, Dr. Loh served in various roles including President, Chief Operating Officer, and Chief Medical Officer from 2014 until June 2019.
Dr. Loh has been a member of our Board of Directors since 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh had served as Chairman of the Board of Directors and Chief Medical Officer. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all R&D pre-proof of concept development phase programs and leading global portfolio prioritization.
Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led multiple successful global registration programs, including for Torisel and Tygacil. He currently serves on the Board of Directors of Eiger Biopharmaceuticals, Inc. and Windtree Pharmaceuticals, Inc. Dr. Loh served as Chairman of the Antimicrobials Working Group (AWG), an industry leading coalition of biotech companies focused on antimicrobial development from 2019 to 2021, and currently serves on its Executive Committee. Dr. Loh served as a Director on the Board of Nivalis from 2012 until the completion of its sale to Alpine Immunotherapeutics in 2017.
Education& Accomplishments
Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
What is Evan Loh's net worth?
The estimated net worth of Evan Loh is at least $2.96 million as of August 9th, 2023. Dr. Loh owns 1,327,981 shares of Paratek Pharmaceuticals stock worth more than $2,961,398 as of April 25th. This net worth estimate does not reflect any other assets that Dr. Loh may own. Additionally, Dr. Loh receives a salary of $1,140,000.00 as CEO at Paratek Pharmaceuticals. Learn More about Evan Loh's net worth.
How old is Evan Loh?
Dr. Loh is currently 64 years old. There are 5 older executives and no younger executives at Paratek Pharmaceuticals. Learn More on Evan Loh's age.
What is Evan Loh's salary?
How do I contact Evan Loh?
Has Evan Loh been buying or selling shares of Paratek Pharmaceuticals?
Evan Loh has not been actively trading shares of Paratek Pharmaceuticals over the course of the past ninety days. Most recently, Evan Loh sold 48,967 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $2.20, for a transaction totalling $107,727.40. Following the completion of the sale, the chief executive officer now directly owns 1,327,981 shares of the company's stock, valued at $2,921,558.20. Learn More on Evan Loh's trading history.
Who are Paratek Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Paratek Pharmaceuticals?
During the last year, insiders at the specialty pharmaceutical company sold shares 4 times. They sold a total of 142,346 shares worth more than $313,161.20. The most recent insider tranaction occured on August, 9th when insider Randall B Brenner sold 27,603 shares worth more than $60,726.60. Insiders at Paratek Pharmaceuticals own 8.0% of the company.
Learn More about insider trades at Paratek Pharmaceuticals. Information on this page was last updated on 8/9/2023.
